Madrigal Pharmaceuticals (MDGL) 10-Q2011 Q1 Quarterly report

Filed: 5 May 11, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: ansamycin, BESP, bone, broker, build, capture, clause, clear, collateral, consideration, customer, dealer, Defense, delivery, Department, distinguish, DoD, element, exclusive, family, flexibility, formally, foundation, fraction, furniture, ganetespib, greatest, iii, inactive, Lien, marrow, newly, Note, ownership, Oxford, pending, perfected, portion, predictor, priority, radiotherapy, ratified, refine, regularly, remote, standard, Subordination, superior, synergy, synthetic, talent, translational, underwriter, unmet, unrelated, Velcade, veterinary

Removed: academic, accelerated, achieving, activation, actively, adjuvant, AKT, allergy, alternative, animal, Anticancer, Antonio, apilimod, ASH, attack, Avastin, biomarker, blast, Boston, BRAF, Brigham, Burkitt, cellular, center, characterized, clinically, colorectal, confirmed, contrast, controlled, Crohn, deliver, designing, diffuse, director, dosing, elevated, Erbitux, ESMO, exploring, FDA, folding, formation, fourth, fulfill, gastrointestinal, generation, GIST, Gleevec, greater, guide, headcount, health, Hematology, Herceptin, higher, Hospital, IASLC, improved, infusion, inhibition, initiated, Institute, intent, kill, KIT, large, listing, locally, longer, lost, low, lymphoma, maintain, manage, metabolic, metastatic, MTD, multinational, mutated, mutation, NCI, Nexavar, Ohio, optimized, osteosarcoma, partner, partnered, PDGFRA, positive, potency, potently, preferred, prevent, previously, printing, prognostic, progressing, pronounced, proper, rapidly, reached, realignment, recent, reimburse, remeasuring, renal, resistant, restart, restructuring, retaspimycin, returned, route, San, schedule, School, selectively, shifting, showing, simultaneously, Society, stromal, structure, suspension, Sutent, SYMMETRY, systemic, tanespimycin, Tarceva, Taxol, termination, tested, tolerated, tyrosine, underlying, University, validated, vasculature, wider, Women, Worcester, workforce

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

MDGL similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATIONS UNDER SECTION 906

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Synta Pharmaceuticals Corp., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report on Form 10-Q for the period ended March 31, 2011 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

	Dated: May 5, 2011	/s/ SAFI R. BAHCALL, PH.D.
		Safi R. Bahcall, Ph.D.
		President and Chief Executive Officer
		(principal executive officer)


	Dated: May 5, 2011	/s/ KEITH S. EHRLICH
		Keith S. Ehrlich
		Vice President, Finance and Administration,
		Chief Financial Officer
		(principal accounting and financial officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.